Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Charles Nicholas Serhan, Ph.D.

Co-Author

This page shows the publications co-authored by Charles Serhan and Nan Chiang.
Connection Strength

19.884
  1. Cysteinyl-specialized proresolving mediators link resolution of infectious inflammation and tissue regeneration via TRAF3 activation. Proc Natl Acad Sci U S A. 2021 Mar 09; 118(10).
    View in: PubMed
    Score: 0.974
  2. Specialized pro-resolving mediator network: an update on production and actions. Essays Biochem. 2020 09 23; 64(3):443-462.
    View in: PubMed
    Score: 0.944
  3. Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions. J Clin Invest. 2019 12 02; 129(12):5294-5311.
    View in: PubMed
    Score: 0.892
  4. Identification of Chemotype Agonists for Human Resolvin D1 Receptor DRV1 with Pro-Resolving Functions. Cell Chem Biol. 2019 02 21; 26(2):244-254.e4.
    View in: PubMed
    Score: 0.834
  5. New maresin conjugates in tissue regeneration pathway counters leukotriene D4-stimulated vascular responses. FASEB J. 2018 07; 32(7):4043-4052.
    View in: PubMed
    Score: 0.790
  6. Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Mol Aspects Med. 2017 Dec; 58:114-129.
    View in: PubMed
    Score: 0.741
  7. Novel Resolvin D2 Receptor Axis in Infectious Inflammation. J Immunol. 2017 01 15; 198(2):842-851.
    View in: PubMed
    Score: 0.727
  8. Identification of resolvin D2 receptor mediating resolution of infections and organ protection. J Exp Med. 2015 Jul 27; 212(8):1203-17.
    View in: PubMed
    Score: 0.659
  9. Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. Biochim Biophys Acta. 2015 Apr; 1851(4):397-413.
    View in: PubMed
    Score: 0.618
  10. Resolution phase lipid mediators of inflammation: agonists of resolution. Curr Opin Pharmacol. 2013 Aug; 13(4):632-40.
    View in: PubMed
    Score: 0.569
  11. Inhaled carbon monoxide accelerates resolution of inflammation via unique proresolving mediator-heme oxygenase-1 circuits. J Immunol. 2013 Jun 15; 190(12):6378-88.
    View in: PubMed
    Score: 0.566
  12. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature. 2012 Apr 25; 484(7395):524-8.
    View in: PubMed
    Score: 0.527
  13. Novel anti-inflammatory--pro-resolving mediators and their receptors. Curr Top Med Chem. 2011; 11(6):629-47.
    View in: PubMed
    Score: 0.481
  14. Anesthetics impact the resolution of inflammation. PLoS One. 2008 Apr 02; 3(4):e1879.
    View in: PubMed
    Score: 0.397
  15. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol. 2008 Mar; 153 Suppl 1:S200-15.
    View in: PubMed
    Score: 0.386
  16. New mechanism for an old drug: aspirin triggers anti-inflammatory lipid mediators with gender implications. Compr Ther. 2006; 32(3):150-7.
    View in: PubMed
    Score: 0.340
  17. Cell-cell interaction in the transcellular biosynthesis of novel omega-3-derived lipid mediators. Methods Mol Biol. 2006; 341:227-50.
    View in: PubMed
    Score: 0.340
  18. Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: a randomized human trial. Arterioscler Thromb Vasc Biol. 2006 Feb; 26(2):e14-7.
    View in: PubMed
    Score: 0.337
  19. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fatty Acids. 2005 Sep-Oct; 73(3-4):163-77.
    View in: PubMed
    Score: 0.332
  20. Aspirin triggers formation of anti-inflammatory mediators: New mechanism for an old drug. Discov Med. 2004 Dec; 4(24):470-5.
    View in: PubMed
    Score: 0.315
  21. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci U S A. 2004 Oct 19; 101(42):15178-83.
    View in: PubMed
    Score: 0.312
  22. Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entrée for resoleomics. Rheum Dis Clin North Am. 2004 Feb; 30(1):69-95.
    View in: PubMed
    Score: 0.298
  23. A novel rat lipoxin A4 receptor that is conserved in structure and function. Br J Pharmacol. 2003 May; 139(1):89-98.
    View in: PubMed
    Score: 0.282
  24. Lipid-derived mediators in endogenous anti-inflammation and resolution: lipoxins and aspirin-triggered 15-epi-lipoxins. ScientificWorldJournal. 2002 Jan 22; 2:169-204.
    View in: PubMed
    Score: 0.259
  25. Anti-microinflammatory lipid signals generated from dietary N-3 fatty acids via cyclooxygenase-2 and transcellular processing: a novel mechanism for NSAID and N-3 PUFA therapeutic actions. J Physiol Pharmacol. 2000 Dec; 51(4 Pt 1):643-54.
    View in: PubMed
    Score: 0.239
  26. Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J Exp Med. 2000 Apr 03; 191(7):1197-208.
    View in: PubMed
    Score: 0.228
  27. Lipoxins, aspirin-triggered 15-epi-lipoxin stable analogs and their receptors in anti-inflammation: a window for therapeutic opportunity. Ernst Schering Res Found Workshop. 2000; (31):143-85.
    View in: PubMed
    Score: 0.224
  28. Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J Clin Invest. 1999 Aug; 104(3):309-16.
    View in: PubMed
    Score: 0.218
  29. Aspirin-triggered 15-epi-lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA4 ELISA. J Pharmacol Exp Ther. 1998 Nov; 287(2):779-90.
    View in: PubMed
    Score: 0.207
  30. Identification and Complete Stereochemical Assignments of the New Resolvin Conjugates in Tissue Regeneration in Human Tissues that Stimulate Proresolving Phagocyte Functions and Tissue Regeneration. Am J Pathol. 2018 04; 188(4):950-966.
    View in: PubMed
    Score: 0.199
  31. Structural insights into Resolvin D4 actions and further metabolites via a new total organic synthesis and validation. J Leukoc Biol. 2018 Jan 29.
    View in: PubMed
    Score: 0.196
  32. Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. Nat Commun. 2018 01 04; 9(1):59.
    View in: PubMed
    Score: 0.195
  33. New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration. Mol Aspects Med. 2018 12; 64:1-17.
    View in: PubMed
    Score: 0.191
  34. A cluster of immunoresolvents links coagulation to innate host defense in human blood. Sci Signal. 2017 Aug 01; 10(490).
    View in: PubMed
    Score: 0.190
  35. Identification and Actions of the Maresin 1 Metabolome in Infectious Inflammation. J Immunol. 2016 12 01; 197(11):4444-4452.
    View in: PubMed
    Score: 0.180
  36. Maresin conjugates in tissue regeneration biosynthesis enzymes in human macrophages. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):12232-12237.
    View in: PubMed
    Score: 0.179
  37. Identification and Actions of a Novel Third Maresin Conjugate in Tissue Regeneration: MCTR3. PLoS One. 2016; 11(2):e0149319.
    View in: PubMed
    Score: 0.171
  38. Resolvin D4 stereoassignment and its novel actions in host protection and bacterial clearance. Sci Rep. 2016 Jan 08; 6:18972.
    View in: PubMed
    Score: 0.170
  39. Maresin 1 Biosynthesis and Proresolving Anti-infective Functions with Human-Localized Aggressive Periodontitis Leukocytes. Infect Immun. 2015 Dec 14; 84(3):658-65.
    View in: PubMed
    Score: 0.169
  40. The Regulation of Proresolving Lipid Mediator Profiles in Baboon Pneumonia by Inhaled Carbon Monoxide. Am J Respir Cell Mol Biol. 2015 Sep; 53(3):314-25.
    View in: PubMed
    Score: 0.166
  41. Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections. Nat Med. 2015 Sep; 21(9):1071-5.
    View in: PubMed
    Score: 0.165
  42. The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Semin Immunol. 2015 May; 27(3):200-15.
    View in: PubMed
    Score: 0.162
  43. Proresolving actions of a new resolvin D1 analog mimetic qualifies as an immunoresolvent. . 2015 May 01; 308(9):L904-11.
    View in: PubMed
    Score: 0.161
  44. Lipid mediators in the resolution of inflammation. Cold Spring Harb Perspect Biol. 2014 Oct 30; 7(2):a016311.
    View in: PubMed
    Score: 0.157
  45. Identification of 14-series sulfido-conjugated mediators that promote resolution of infection and organ protection. Proc Natl Acad Sci U S A. 2014 Nov 04; 111(44):E4753-61.
    View in: PubMed
    Score: 0.156
  46. Cell-cell interactions and bronchoconstrictor eicosanoid reduction with inhaled carbon monoxide and resolvin D1. . 2014 Nov 15; 307(10):L746-57.
    View in: PubMed
    Score: 0.155
  47. Cutting edge: Parathyroid hormone facilitates macrophage efferocytosis in bone marrow via proresolving mediators resolvin D1 and resolvin D2. J Immunol. 2014 Jul 01; 193(1):26-9.
    View in: PubMed
    Score: 0.152
  48. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. . 2014 Jul 01; 307(1):C39-54.
    View in: PubMed
    Score: 0.151
  49. Plasticity of leukocytic exudates in resolving acute inflammation is regulated by MicroRNA and proresolving mediators. Immunity. 2013 Nov 14; 39(5):885-98.
    View in: PubMed
    Score: 0.147
  50. Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chem Biol. 2013 Feb 21; 20(2):188-201.
    View in: PubMed
    Score: 0.139
  51. Self-limited versus delayed resolution of acute inflammation: temporal regulation of pro-resolving mediators and microRNA. Sci Rep. 2012; 2:639.
    View in: PubMed
    Score: 0.135
  52. Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol. 2012 May; 180(5):2018-27.
    View in: PubMed
    Score: 0.131
  53. Metabolomics-lipidomics of eicosanoids and docosanoids generated by phagocytes. Curr Protoc Immunol. 2011 Nov; Chapter 14:Unit 14.26.
    View in: PubMed
    Score: 0.127
  54. MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. FASEB J. 2011 Feb; 25(2):544-60.
    View in: PubMed
    Score: 0.118
  55. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A. 2010 Jan 26; 107(4):1660-5.
    View in: PubMed
    Score: 0.112
  56. Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood. 2008 Aug 01; 112(3):848-55.
    View in: PubMed
    Score: 0.100
  57. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008 May; 8(5):349-61.
    View in: PubMed
    Score: 0.100
  58. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature. 2007 Jun 14; 447(7146):869-74.
    View in: PubMed
    Score: 0.094
  59. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol. 2007 Mar 15; 178(6):3912-7.
    View in: PubMed
    Score: 0.092
  60. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev. 2006 Sep; 58(3):463-87.
    View in: PubMed
    Score: 0.089
  61. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol. 2005 Apr 01; 174(7):4345-55.
    View in: PubMed
    Score: 0.081
  62. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med. 2005 Mar 07; 201(5):713-22.
    View in: PubMed
    Score: 0.080
  63. Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J Immunol. 2003 Jun 15; 170(12):6266-72.
    View in: PubMed
    Score: 0.071
  64. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med. 2002 Nov; 8(11):1296-302.
    View in: PubMed
    Score: 0.068
  65. Cutting edge: nociceptin stimulates neutrophil chemotaxis and recruitment: inhibition by aspirin-triggered-15-epi-lipoxin A4. J Immunol. 2001 Mar 15; 166(6):3650-4.
    View in: PubMed
    Score: 0.061
  66. Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. Am J Pathol. 2001 Jan; 158(1):3-9.
    View in: PubMed
    Score: 0.060
  67. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med. 2000 Oct 16; 192(8):1197-204.
    View in: PubMed
    Score: 0.059
  68. Oxidoreductases in lipoxin A4 metabolic inactivation: a novel role for 15-onoprostaglandin 13-reductase/leukotriene B4 12-hydroxydehydrogenase in inflammation. J Biol Chem. 2000 Aug 18; 275(33):25372-80.
    View in: PubMed
    Score: 0.059
  69. Formation of endogenous "antiinflammatory" lipid mediators by transcellular biosynthesis. Lipoxins and aspirin-triggered lipoxins inhibit neutrophil recruitment and vascular permeability. Am J Respir Crit Care Med. 2000 Feb; 161(2 Pt 2):S95-S101.
    View in: PubMed
    Score: 0.056
  70. Addendum: Resolving Inflammation: Synthesis, Configurational Assignment, and Biological Evaluations of RvD1n-3?DPA. Chemistry. 2019 11 27; 25(66):15212.
    View in: PubMed
    Score: 0.055
  71. Lipoxin and aspirin-triggered 15-epi-lipoxin cellular interactions anti-inflammatory lipid mediators. Clin Chem Lab Med. 1999 Mar; 37(3):299-309.
    View in: PubMed
    Score: 0.053
  72. Resolving Inflammation: Synthesis, Configurational Assignment, and Biological Evaluations of RvD1n-3?DPA. Chemistry. 2019 Jan 28; 25(6):1476-1480.
    View in: PubMed
    Score: 0.052
  73. Specific oxylipins enhance vertebrate hematopoiesis via the receptor GPR132. Proc Natl Acad Sci U S A. 2018 09 11; 115(37):9252-9257.
    View in: PubMed
    Score: 0.051
  74. Biosynthesis of D-Series Resolvins in Skin Provides Insights into their Role in Tissue Repair. J Invest Dermatol. 2018 09; 138(9):2051-2060.
    View in: PubMed
    Score: 0.050
  75. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J. 2016 08; 30(8):2792-801.
    View in: PubMed
    Score: 0.043
  76. Design and synthesis of novel prostaglandin E2 ethanolamide and glycerol ester probes for the putative prostamide receptor(s). Tetrahedron Lett. 2015 Mar 11; 56(11):1411-1415.
    View in: PubMed
    Score: 0.040
  77. Novel tail and head group prostamide probes. Bioorg Med Chem Lett. 2015 Mar 15; 25(6):1228-31.
    View in: PubMed
    Score: 0.040
  78. The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol. 2013 Dec; 170(8):1449-58.
    View in: PubMed
    Score: 0.037
  79. Resolvin D1 and aspirin-triggered resolvin D1 regulate histamine-stimulated conjunctival goblet cell secretion. Mucosal Immunol. 2013 Nov; 6(6):1119-30.
    View in: PubMed
    Score: 0.035
  80. Resolvin E1 and chemokine-like receptor 1 mediate bone preservation. J Immunol. 2013 Jan 15; 190(2):689-94.
    View in: PubMed
    Score: 0.034
  81. Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. Invest Ophthalmol Vis Sci. 2009 Oct; 50(10):4743-52.
    View in: PubMed
    Score: 0.027
  82. RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis. FASEB J. 2006 Feb; 20(2):401-3.
    View in: PubMed
    Score: 0.021
  83. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem. 2003 Oct 31; 278(44):43807-17.
    View in: PubMed
    Score: 0.018
  84. Aspirin-triggered 15-epi-lipoxin A4 biosynthesis in rat liver cells. Adv Exp Med Biol. 2002; 507:199-209.
    View in: PubMed
    Score: 0.016
  85. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J. 2000 Jul; 16(1):44-9.
    View in: PubMed
    Score: 0.015
  86. Hepatocytes are a rich source of novel aspirin-triggered 15-epi-lipoxin A(4). Am J Physiol. 1999 11; 277(5):C870-7.
    View in: PubMed
    Score: 0.014
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.